Contents
Clinical research in Nebraska handles the toughest medical challenges. Each trial is designed to provide patients with new and improved treatments for treating particular diseases.
Clinical trials determine how well therapies and drugs work on people before they are available to the general public. You can participate in transitional research that can save lives. We are here to simplify the process and connect you to research trials in your local area.
Clinical Trials For Disease Areas in Nebraska
Clinical research trials in Nebraska excel in studies ranging from oncology to neurology, heart-related ailments, diabetes, and musculoskeletal disorders.
For example, the Nebraska Business Development Center (NBDC) is helping a recently established research team in Nebraska to bring new drugs for hearing loss into clinical trials. These drugs could prove useful for different patients, especially veterans.
By participating in trials, you can become an integral component of medical science. You can directly impact the development of safer and more effective treatments. Join us in the pursuit of better healthcare. Check the list of clinical trials below to apply.
Consent for Use of Stored Patient Specimens for Future Testing
Recruiting
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing.
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
09/20/2024
Locations: Specialty Care Center CRS 1505, Omaha, Nebraska
Specialty Care Center CRS 1505, Omaha, Nebraska
Conditions: HIV Infections
Mucopolysaccharidosis I (MPS I) Registry
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the lon... Read More
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase)
* To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I
* To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care Read Less
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
Conditions: Mucopolysaccharidosis I (MPS I)
Fabry Disease Registry & Pregnancy Sub-registry
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of F... Read More
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
* To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
* To characterize and describe the Fabry population as a whole;
* To evaluate the long-term safety and effectiveness of Fabrazyme®
Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
Conditions: Fabry Disease
Pompe Disease Registry Protocol
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of t... Read More
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Pompe disease population.
* To evaluate the long-term effectiveness of alglucosidase alfa. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Omaha, Nebraska
Not set, Omaha, Nebraska
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
Recruiting
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural... Read More
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Gaucher disease population.
* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.
Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/12/2025
Locations: University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
The Pediatric Anesthesia Quality Improvement Project
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events. Read Less
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/15/2025
Locations: Children's Hospital and Medical Center, Omaha, Nebraska
Children's Hospital and Medical Center, Omaha, Nebraska
Conditions: Surgery, Anesthesia, Children
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Read Less
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: Children's Hospital and Medical Center of Omaha, Omaha, Nebraska +1 locations
Children's Hospital and Medical Center of Omaha, Omaha, Nebraska
University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science
Recruiting
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inh... Read More
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inheritance is responsible for many common medical disorders, including hypertension, myocardial infarction, diabetes and cancer. This type of inheritance pattern appears to involve environmental factors as well as a combination of genetic variations that together can predispose to or produce congenital anomalies, such as congenital diaphragmatic hernia.
Our study is designed to establish a small, well-defined genetic resource consisting of 1) Nuclear families suitable for linkage analysis by parametric,non-parametric (e.g. sib pairs, TDT) and association techniques, 2) Individuals with congenital diaphragmatic hernia who can be directly screened for allelic variation in candidate genes, and 3) Individuals who can serve as controls (are unaffected by congenital diaphragmatic hernia). Neonates and their families will be collected from homogenous and heterogeneous populations. By characterizing diverse populations, it should be possible to increase the likelihood of demonstration of genetic variation in selected candidate genes that can then be used in association and linkage studies in individual subjects with congenital diaphragmatic hernia. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: Children's Hospital of Omaha/ University of Nebraska, Omaha, Nebraska
Children's Hospital of Omaha/ University of Nebraska, Omaha, Nebraska
Conditions: Congenital Diaphragmatic Hernia
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
04/15/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Paid Clinical Trials in Nebraska
One big benefit of paid clinical trials is the financial incentive. Experts can pay volunteers relatively well for their time and contributions. Often, the payment ranges from a couple of hundred to a few thousand dollars – depending on the trial phase.
Phase I pays the most, while Phase IV pays the least. NE paid clinical trials are an effective option for finding adequate treatments that are otherwise difficult to afford.
Clinical Trials For Health Volunteers in Nebraska
Healthy volunteers are a valuable component of clinical research. People, like yourself, can help find cures that are suitable for specific health conditions. Trials are here to test drug effectiveness, risks, and potency.
Health volunteers can help research teams in Nebraska learn more about the different factors to prevent a disease. They can also provide crucial feedback for vaccine development. Check the list below if you want to apply.
Integrated Cancer Repository for Cancer Research
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies. Read Less
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: Mary Lanning Healthcare, Morrison Cancer Center, Hastings, Nebraska +6 locations
Mary Lanning Healthcare, Morrison Cancer Center, Hastings, Nebraska
Faith Regional Health Services, Carson Cancer Center, Norfolk, Nebraska
Great Plains Regional Medical Center, North Platte, Nebraska
Methodist Estabrook Cancer Center, Omaha, Nebraska
Nebraska Methodist Health System, Omaha, Nebraska
University of Nebraska Medical Center, Omaha, Nebraska
Regional West Health Services, Scottsbluff, Nebraska
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Recruiting
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults. Read Less
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/30/2025
Locations: Velocity Clinical Research Lincoln ( Site 0004), Lincoln, Nebraska +1 locations
Velocity Clinical Research Lincoln ( Site 0004), Lincoln, Nebraska
Velocity Clinical Research, Omaha ( Site 0005), Omaha, Nebraska
Conditions: Healthy
Relative Bioavailability of NX-5948 Tablets Vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
Recruiting
This is a 2-cohort, fixed-sequence, 3-period, relative bioavailability, food-effect, and drug-drug interaction study. It is an open-label study evaluating the relative bioavailability of NX-5948 tablets compared to capsules, and the effect of food and an acid-reducing agent on the pharmacokinetics (PK) of NX-5948.
This is a 2-cohort, fixed-sequence, 3-period, relative bioavailability, food-effect, and drug-drug interaction study. It is an open-label study evaluating the relative bioavailability of NX-5948 tablets compared to capsules, and the effect of food and an acid-reducing agent on the pharmacokinetics (PK) of NX-5948. Read Less
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
12/13/2024
Locations: Celerion, Lincoln, Nebraska
Celerion, Lincoln, Nebraska
Conditions: Healthy Volunteer
The Short-term Verbal Memory Endophenotype for Developmental Language Disorder Language Disorder
Recruiting
The goal of this clinical trial is to determine how memory and attention affect the ability of children with developmental language disorder (DLD) to learn and use new vocabulary.
The goal of this clinical trial is to determine how memory and attention affect the ability of children with developmental language disorder (DLD) to learn and use new vocabulary. Read Less
Gender:
ALL
Ages:
Between 5 years and 10 years
Trial Updated:
05/05/2025
Locations: Boys Town National Research Hospital, Omaha, Nebraska
Boys Town National Research Hospital, Omaha, Nebraska
Conditions: Developmental Language Disorder, Healthy Subjects
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
Recruiting
This study will be conducted to assess the safety, tolerability, and pharmacokinetics of INCB000631 when administered orally to healthy adult participants.
This study will be conducted to assess the safety, tolerability, and pharmacokinetics of INCB000631 when administered orally to healthy adult participants. Read Less
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
08/15/2025
Locations: Celerion, Inc, Lincoln, Nebraska
Celerion, Inc, Lincoln, Nebraska
Conditions: Healthy Participants
Medical Discoveries and Innovation in Nebraska
Many noteworthy medical achievements come from Nebraska research institutions. They’ve left a mark on the field of healthcare. Some of these notable breakthroughs include:
- Virtual incision: In 2016, the University of Nebraska Medical Center did the very first human surgery with the help of a miniaturized robot. This medical innovation helps reduce the costs of abdominal surgeries and patient recovery time.
- Revolutionary stroke treatment: Scientists in Nebraska created a device known as Galileo. It can gently reverse the impact of a stroke on adults, kids, and infants, without any invasive procedures. This device relies on innovative methods for analyzing blood flow.
- Multidisciplinary Cancer Research: The Eppley Institute for Research in Cancer and Allied Diseases is a leader in cancer research. Their contribution helped scientists better understand cancer biology and develop new therapies.
Why Nebraska Is A Great Place For Clinical Research
There is a lack of diversity in data. Nebraska clinical research can greatly benefit from volunteers from different ethnicities and racial makeup. Data shows that 77.4% of the state’s population is White, 12% is Hispanic, 5% is Black, 2.7% is Asian, 2.1% is Multiracial, and 0.8% is American Indian.